Biogen and Biotech

Selected news for the company - Biogen, and the healthcare topic - Biotech. We have 798 shared news items for this connection to-date.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
1/12/2022 JPM22, Day 3: BeiGene, Ionis promise 'tidal wave' of new drugs; Roche launches smart, point-of-care glucose monitor | FierceBiotech FierceBiotech ... Biotech , and follow Fierce Pharma's coverage .Our Day 1 conference tracker is available here , and all the Day 2 action is wrapped here . We'll finish off the event with another compilation of our stories on Thursday's Day 4.UPDATED: Wednesday 10:33 a.m. ETFlush with $2 billion in cash and recent partnerships with AstraZeneca and Biogen , Ionis Pharmaceuticals expects to have a ‚Autidal wave of drugs‚Au reaching the market ...
1/8/2022 Barron's Latest Picks And Pans: Visa, AT&T, Biogen, Robinhood And More | Markets Insider Business Insider ... fuels amid increased attention to climate change.Find out why the first initial public offerings of 2022, a trio of biotech companies, including Amylyx Pharmaceuticals Inc (NASDAQ:AMLX), and Vigil Neuroscience Inc (NASDAQ:VIGL), went ... Has Played Out. The Stock Has ‚AoLimited‚Ao Downside Risks.""Biogen‚Aos Alzheimer‚Aos Drug Has Another Shot at Success," by Josh Nathan-Kazis looks at how Biogen Inc's (NASDAQ: BIIB ) Alzheimer‚Aos disease therapy ...
1/8/2022 Barron's Latest Picks And Pans: Visa, AT&T, Biogen, Robinhood And More ... fuels amid increased attention to climate change.Find out why the first initial public offerings of 2022, a trio of biotech companies, including Amylyx Pharmaceuticals Inc (NASDAQ:AMLX), and Vigil Neuroscience Inc (NASDAQ:VIGL), went ... Played Out. The Stock Has ‚AoLimited‚Ao Downside Risks.‚Au‚AuBiogen‚Aos Alzheimer‚Aos Drug Has Another Shot at Success,‚Au by Josh Nathan-Kazis looks at how Biogen Inc‚Aos (NASDAQ:BIIB) Alzheimer‚Aos ...
1/7/2022 Friday, Jan. 7: Costs of nursing shortages | Why a Swiss company picked AZ for its HQ | Ruling unlikely to end mandate uncertainty Warehouse construction boosts industrial market To view this email as a webpage, click here Sponsored by: By Eric Mandel ‚A¢ January 07, 2022The stakes are high next week for Biogen Inc. It'll be the biotech company's first chance to make a case to investors and the press after months of public setbacks, mostly associated with its newly approved Alzheimer's drug.Biogen executives are expected to take the virtual stage ...
12/23/2021 7 challenges that could make or break Biogen's 2022 - STAT STAT Biotech 7 challenges that could make or break Biogen‚Aos 2022 By Damian Garde , Adam Feuerstein and Rachel Cohrs Dec. 23, 2021ReprintsRuby Wallau for STATCan Biogen pull itself back from the brink?The company is ending 2021 with dismal sales of its treatment for Alzheimer‚Aos disease and its stock depressed. Management is slashing the drug‚Aos price and cutting expenses ...
12/20/2021 Biogen slashes price of Aduhelm in half, plans $500M in cost-cutting STAT Biotech Biogen slashes price of Alzheimer‚Aos drug Aduhelm in half, plans $500M in cost-cutting By Adam Feuerstein Dec. 20, 2021ReprintsSteven Senn/APB iogen said Monday that it has reduced the price of its Alzheimer‚Aos drug Aduhelm by half and is planning a series of cost-cutting measures across the company next year that aim to save $500 million.The moves follow a disappointing commercial ...
11/30/2021 'What it takes': As Lilly's Alzheimer's drug approaches FDA, launch leader feels 'amplified' sense of excitement FierceBiotech ... women in Alzheimer's disease. To read more about the series, please see our introduction page here . The first profile on Biogen's Maha Radhakrishnan is available here .Back when Brandy Matthews, M.D., was seeing Alzheimer‚Aos ... is amazing,‚Au Matthews said in an interview with Fierce Biotech.Now, Matthews is overseeing a team at Eli Lilly that‚Aos hoping to soon launch donanemab as the second new Alzheimer‚Aos treatment believed ...
10/28/2021 Why InflaRx Shares Are Ripping Higher Thursday | Benzinga Benzinga ... Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOsSell-Side Review Of Data Reason Behind Upside? The stock reaction was muted following the Wednesday morning data release.After opening Wednesday's session up 1.8% at $2.91, the stock traded in a $2.78-$3 range before ending unchanged at $2.86.Following the release of the data, SVB Leerink analyst Joseph Schwartz reiterated ...
10/20/2021 Biogen Shareholders Face the Waiting Game - WSJ The Wall Street Journal For the time being, sales of Biogen ‚Aos BIIB 1.37% would-be blockbuster Alzheimer‚Aos disease treatment Aduhelm are stuck in the mud. Until that changes, investors shouldn‚Aot expect the biotech giant‚Aos share price to look much different.Its third-quarter results were better than most expected. Sales of $2.8 billion and adjusted earnings of $4.77 a share topped analyst estimates, and Biogen raised its sales and profit ...
10/19/2021 Market highlights: Bitcoin near ATH, Disney drags DJ30 down, oil reaches new 7-year high ... Biotech firm Biogen was one of the biggest losers in the SPX500, which was marginally in the green yesterday. Their share price dropped by over 4% after they reported their new ALS medication had not passed a phase three clinical trial. Albeit gaining around 10% y/y, the shares have fallen double digits over the past three months. Saks Fifth Avenue to list e-commerce branch Yesterday, reports surfaced that ...
10/7/2021 Intergalactic Therapeutics launches with $75M to build a new type of gene therapy | BioPharma Dive Early in 2020, Michael Ehlers, a former Biogen executive turned venture capitalist and biotech entrepreneur, was brainstorming ways to create a different kind of gene therapy.Amid a genetic medicine boom, dozens of companies had built and advanced into testing experimental therapies that used the same principles, tucking functional genes into viruses capable of shuttling DNA into cells.Ehlers and the startup he began to build that spring with his ...
10/2/2021 Choroideremia Pipeline: Industry Analysis, Drugs, Pipeline, Treatment and Key Companies by DelveInsight | 4D Molecular Therapeutics, Roche, Biogen and Many Others Choroideremia Pipeline: Industry Analysis, Drugs, Pipeline, Treatment and Key Companies by DelveInsight 4D Molecular Therapeutics, Roche, Biogen and Many Others Choroideremia is an X-linked chorioretinal dystrophy characterized by progressive degeneration of the choroid, retinal ... companies such as NightstaRx Ltd/Biogen, 4D Molecular Therapeutics, Curative Biotech, Therapeutics, Spark therapeutics/Roche, and others are developing potential drug candidates to improve the Choroideremia treatment scenario. - In June 2021, NightstaRx Ltd announced that ...
10/2/2021 Choroideremia Pipeline: Industry Analysis, Drugs, Pipeline, Treatment and Key Companies by DelveInsight | 4D Molecular Therapeutics, Roche, Biogen and Many Others Choroideremia Pipeline: Industry Analysis, Drugs, Pipeline, Treatment and Key Companies by DelveInsight 4D Molecular Therapeutics, Roche, Biogen and Many Others Choroideremia is an X-linked chorioretinal dystrophy characterized by progressive degeneration of the choroid, retinal ... companies such as NightstaRx Ltd/Biogen, 4D Molecular Therapeutics, Curative Biotech, Therapeutics, Spark therapeutics/Roche, and others are developing potential drug candidates to improve the Choroideremia treatment scenario. - In June 2021, NightstaRx Ltd announced that ...
10/2/2021 Choroideremia Pipeline: Industry Analysis, Drugs, Pipeline, Treatment and Key Companies by DelveInsight | 4D Molecular Therapeutics, Roche, Biogen and Many Others Choroideremia Pipeline: Industry Analysis, Drugs, Pipeline, Treatment and Key Companies by DelveInsight 4D Molecular Therapeutics, Roche, Biogen and Many Others Choroideremia is an X-linked chorioretinal dystrophy characterized by progressive degeneration of the choroid, retinal ... companies such as NightstaRx Ltd/Biogen, 4D Molecular Therapeutics, Curative Biotech, Therapeutics, Spark therapeutics/Roche, and others are developing potential drug candidates to improve the Choroideremia treatment scenario. - In June 2021, NightstaRx Ltd announced that ...
10/2/2021 Choroideremia Pipeline: Industry Analysis, Drugs, Pipeline, Treatment and Key Companies by DelveInsight | 4D Molecular Therapeutics, Roche, Biogen and Many Others Choroideremia Pipeline: Industry Analysis, Drugs, Pipeline, Treatment and Key Companies by DelveInsight 4D Molecular Therapeutics, Roche, Biogen and Many Others Choroideremia is an X-linked chorioretinal dystrophy characterized by progressive degeneration of the choroid, retinal ... companies such as NightstaRx Ltd/Biogen, 4D Molecular Therapeutics, Curative Biotech, Therapeutics, Spark therapeutics/Roche, and others are developing potential drug candidates to improve the Choroideremia treatment scenario. - In June 2021, NightstaRx Ltd announced that ...
9/30/2021 Biotech incubator Sporos' new CEO arrives from Ovid with Biogen, Bristol Myers experience | FierceBiotech FierceBiotech ... biotech incubator Sporos Bioventures.Rakhit hit the exit at Ovid as president and chief medical officer after the biotech's lead therapy failed a phase 3 trial in Angelman syndrome. Now, he's taking on the CEO post at Sporos, which launched with $38.1 million in May.Prior to his five-year run at Ovid, Rakhit was in various vice president and senior vice president roles at Biogen for nearly five years ...
9/22/2021 Boston Labs and Germfree Launch Mobile Cell and Gene Therapy (CGT) Manufacturing Platform | Business Wire Business Wire ... biotech companies. 18 of the top 20 biopharmas have a major presence in the area, including Biogen, Novartis, Sanofi and Takeda and other leading companies such as Moderna, Crispr Therapeutics, bluebird bio and Avrobio .Jon Mason, CEO of Boston Labs said: ‚AuAs the cell and gene therapy industry continues to grow, easier on-site access to cleanroom manufacturing facilities will likely be highly valued. Our pivotal partnership with Germfree Laboratories ...
9/22/2021 Boston Labs and Germfree Launch Mobile Cell and Gene Therapy (CGT) Manufacturing Platform Business Wire ... biotech companies. 18 of the top 20 biopharmas have a major presence in the area, including Biogen, Novartis, Sanofi and Takeda and other leading companies such as Moderna, Crispr Therapeutics, bluebird bio and Avrobio . Jon Mason, CEO of Boston Labs said: ‚AuAs the cell and gene therapy industry continues to grow, easier on-site access to cleanroom manufacturing facilities will likely be highly valued. Our pivotal partnership with Germfree Laboratories ...
9/22/2021 The Ridgway Record ... biotech companies. 18 of the top 20 biopharmas have a major presence in the area, including Biogen, Novartis, Sanofi and Takeda and other leading companies such as Moderna, Crispr Therapeutics, bluebird bio and Avrobio .Jon Mason, CEO of Boston Labs said: ‚AuAs the cell and gene therapy industry continues to grow, easier on-site access to cleanroom manufacturing facilities will likely be highly valued. Our pivotal partnership with Germfree Laboratories ...
8/27/2021 Cassava Craters After Lab Denies Involvement in Alzheimer's Data ... Cassava Sciences Inc. plummeted as much 29% on Friday after a lab denied it had prepared recent results for the biotech‚Aos lead product, an experimental Alzheimer‚Aos disease treatment. The denial counters a Wednesday ... more than 700% rally was fueled by the approval of Biogen Inc.‚Aos Aduhelm ‚Ai the first new Alzheimer‚Aos disease treatment in over a decade ‚Ai as well as the recent retail trading frenzy ...
8/27/2021 Cassava Craters After Lab Denies Involvement in Alzheimer's Data Yahoo News ... Cassava Sciences Inc. plummeted as much 29% on Friday after a lab denied it had prepared recent results for the biotech‚Aos lead product, an experimental Alzheimer‚Aos disease treatment.The denial counters a Wednesday ... more than 700% rally was fueled by the approval of Biogen Inc.‚Aos Aduhelm -- the first new Alzheimer‚Aos disease treatment in over a decade -- as well as the recent retail trading frenzy.More stories ...
8/27/2021 Cassava Craters After Lab Denies Involvement in Alzheimer's Data ... Cassava Sciences Inc. plummeted as much 29% on Friday after a lab denied it had prepared recent results for the biotech‚Aos lead product, an experimental Alzheimer‚Aos disease treatment. The denial counters a Wednesday ... more than 700% rally was fueled by the approval of Biogen Inc.‚Aos Aduhelm ‚Ai the first new Alzheimer‚Aos disease treatment in over a decade ‚Ai as well as the recent retail trading frenzy ...
8/25/2021 Warren Buffett Sold Off This Biotech Stock. Should You? - NewsBreak ... biotech Biogen ( NASDAQ:BIIB ). Buffett and the rest of his investing team have spoken, but should the rest of us follow their lead and stay far away from Biogen's stock?Why Biogen might be a buy Perhaps the biggest reason to consider purchasing shares of Biogen is the recent approval of Aduhelm , the company's drug for Alzheimer's disease. Aduhelm is the first Alzheimer's drug approved by the U.S. Food and ...
8/25/2021 Warren Buffett Sold Off This Biotech Stock. Should You? ... biotech Biogen (NASDAQ: BIIB) . Buffett and the rest of his investing team have spoken, but should the rest of us follow their lead and stay far away from Biogen's stock?Perhaps the biggest reason to consider purchasing shares of Biogen is the recent approval of Aduhelm , the company's drug for Alzheimer's disease. Aduhelm is the first Alzheimer's drug approved by the U.S. Food and Drug Administration that goes to the ...
8/24/2021 Waste-Derived Biogas Market by Top Key Players are Clarke Energy,Sarawak Energy,Cargill Inc.,Biogas Technology Ltd.,Bedminster International ... Biotech Energy AG,Bekon Biogas Energy Inc.,Biogen Greenfinch,ADI Systems Inc Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins. This report studies the Waste-Derived Biogas Market size by players, regions, types and end industries, history data 2013-2020 and forecast data 2019-2026; this ...